Published: 2019-11-09

Acne & Rosacea

Clinical Safety and Pharmacokinetics of FMX101 4% Topical Minocycline Foam in Pediatric Patients for the Treatment of Moderate-to-Severe Acne Vulgaris

L Eichenfield, L Stein Gold, N Silverberg, T Raoof, D Hooper, A Moore, M Zaiac, T Sullivan, L Kircik, E Lain, S Dhawan, T Jones, J Weiss, Z Draelos, H Ellman, T deVries, J Jankicevic, I Stuart

Page S2

Ex Vivo Assessment of FMX101 & FMX103 Human Skin Permeation and Penetration

Russell Elliott, Gary Lawrence, Yohan Hazot, Lenny Margulis, Vassilis Stakias, Iain Stuart

Page S3

Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial

Zoe Draelos, Fran Cook-Bolden, Lawrence Green, Eric Guenin, Gina Martin, Radhakrishnan Pillai

Page S9

DFD 29, a low dose oral minocycline, shows significant improvement in quality of life in subjects with papulopustular rosacea

Linda Stein Gold, Joshua Zeichner, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi

Page S10

DFD-29, a low dose oral minocycline, demonstrates superior efficacy as compared to placebo and Oraycea ® Capsules (doxycycline HCl) in subjects with papulopustular rosacea

Athanasios Tsianakas, Neal Bhatia, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi

Page S11

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study

D Thaci, K Papp, K Gordon, A Morita, M Gooderham, P Foley, E Alemano, R Kisa, Y Elbez, H Ren, S Banerjee

Page S12

Lack of ECG effects of BMS-986165, an oral, selective tyrosine kinase 2 (TYK2) inhibitor: results from a thorough QT study in healthy subjects

IG Girgis, A Chimalakonda, JP Jones III, R Dockens, D Marchisin, R Darbenzio, S Singhal, J Throup, S Banerjee

Page S13

Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial

C.E.M. Griffiths, K.A. Papp, M Song, M Miller, Y You, Y-K Shen, C Han, A Blauvelt

Page S17

Real World Patient Perceptions of the use of Calcipotriene Foam 0.005% in the Treatment of Plaque Psoriasis

Francisco Kerdel, Christina Don, Renata Block, Caitlin Lewis, Rhonda Schreiber

Page S19

Long-term Efficacy and Safety of Brodalumab in Patients With or Without History of Psoriatic Arthritis: Analysis of Two Phase 3 Psoriasis Studies

Alice Gottlieb, Alan Menter, Paul Yamauchi, George Han, Radhakrishnan Pillai, Tina Lin, Abby Jacobson

Page S21

Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration

Benjamin Ehst, George Han, Scott Guenthner, Kimberly Eads, Abby Jacobson

Page S25

Long-term Efficacy, Safety, and Patient-Reported Outcomes in a Phase 2 Study of Brodalumab

Mark Lebwohl, Andrew Blauvelt, Alan Menter, Kim Papp, Abby Jacobson

Page S26

Optimized Formulation for Topical Application of a Fixed Combination Halobetasol/Tazarotene Lotion Using Polymeric Emulsion Technology

Emil A Tanghetti, Linda Stein Gold, James Q Del Rosso, Stefan Weiss, Tina Lin, Arturo Angel, Radhakrishnan Pillai

Page S27

Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study

Andrew Blauvelt, Kim A Papp, Joseph F Merola, Alice B Gottlieb, Nancy Cross, Cindy Madden, Luke Peterson, Christopher Cioffi, Christopher EM Griffiths

Page S34

Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

K Gordon, R.B. Warren, A.B. Gottlieb, A Blauvelt, D Thaci, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich

Page S36

Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

K Gordon, R.B. Warren, A.B. Gottlieb, A. Blauvelt, D Thaci, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich

Page S37

Xerosis

A Comparison of Efficacy among Therapeutic Moisturizing Creams

CE Arrowitz, LI Jiang, PD Hino, MJ Babcock, TM Weber

Page S44

Skin Cancer

A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA and narrowband red light in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT)

V Laquer, S Bruce, T Schlesinger, N Zeitouni, A Torres, J Cohen, J Tu, W Hanke, M Goldman, D Ozog, O Markowitz, M Gold, M Nestor, B Berman, G Munavalli, D Pariser

Page S48

Multidisciplinary Expert-Driven Consensus on the Evolving Treatment of Patients with Advanced Cutaneous Squamous Cell Carcinoma

Michael R Migden, Todd E Schlesinger, Chrysalyne D Schmults, Scott M Dinehart, Robert L Ferris, Morganna Freeman, Valerie Guild, Shlomo Koyfman, Anna C Pavlick, Gregory T Wolf, Guilherme Rabinowits, Neil Swanson

Page S50

Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo

Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandala, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Laurent Mortier, Caroline Robert, Jacob Schachter, Christine-Elke Ortmann, Egbert de Jong, Edward Gasal, Richard Kefford, John M Kirkwood, Georgina V Long

Page S53

Hyperhidrosis

Dermatopharmacology